If we don't know what the actual cost of components is going forward, you know, those debt assumptions kind of are also in flux. So, it's really playing chess on four levels here. And it's very very difficult to give you um a real conclusion one way or the other. I just think it's a major issue that's going to increase volatility in the first half of 26. >> Well, and before we get to the first half of 26, we got Oracle earnings coming up, which sort of sits squarely at that debt concern that you are talking ...

活动开场 - 公司举办第12届年度社会影响与可持续发展活动 [1] - 演讲者Mavic Cuevas进行开场并宣读安全港声明 [1] - 信息中包含涉及已知和未知风险的前瞻性陈述 [1] 监管文件 - 相关因素描述可参考公司向美国证券交易委员会提交的20-F表格和最近的6-K表格季度业绩 [1] 议程安排 - 演讲者Steffen将正式开启活动并设定基调 [2]

Memo also reportedly mentions vaccines for flu and pneumonia. ...

Key Takeaways CORT's revenues are driven by Korlym, which posted $559.3M in nine-month sales in 2025, up 13.4% y/y.The company expects full-year 2025 revenues of $800M-$850M and sustained Korlym growth.Corcept filed NDAs for relacorilant in Cushing's and ovarian cancer, with FDA decisions due in 2025 and 2026.Corcept Therapeutics (CORT) has been making meaningful progress with its sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome or endogenous hypercortisolism. Cur ...

Key Takeaways Amgen shares jumped almost 16% in a month on strong Q3 results and higher sales guidance.Growing demand for key drugs, new products and biosimilars is driving Amgen's revenue gains.Amgen's expanding pipeline, including MariTide, offers multiple upcoming catalysts.Amgen’s (AMGN) stock has risen almost 16% in a month. A lot of this price increase is due to strong third-quarter 2025 results, wherein both the top and bottom lines exceeded expectations. Amgen also raised its sales guidance for the ...

The FDA approval of LYMPHIR was based on data from Pivotal Study 302 (NCT01871727), which evaluated the efficacy and safety of LYMPHIR in patients with Stage I–III CTCL who had received at least one prior systemic treatment. The study demonstrated an Objective Response Rate (ORR) of 36.2%, with 84% of evaluable patients experiencing a reduction in skin tumor burden. Moreover, LYMPHIR demonstrated meaningful activity on severe pruritus (itchiness), a significant quality of life issue for CTCL patients. Media ...

Treasuries fell as US trading returned to normal after last week’s holiday, with a surge of new corporate bond supply to begin the last month of the year. Most Read from Bloomberg Yields accelerated higher during US morning — led by long-maturity tenors — after Merck & Co. slated an eight-part bond offering that includes 20-, 30- and 40-year tranches. Government bonds globally were already under pressure as Japan’s 10-year yield jumped to the highest level since 2008 on the prospect of a Bank of Japan in ...

公司概况 - 公司是一家提供快速、易获取、信息丰富且可操作的商业和金融新闻内容的全球性财经新闻和在线广播机构 [2] - 内容由经验丰富且合格的新闻记者团队独立制作 [2] - 新闻团队覆盖全球主要金融和投资中心，在伦敦、纽约、多伦多、温哥华、悉尼和珀斯设有分社和演播室 [2] 内容专长与覆盖范围 - 公司在中型和小型市值市场领域是专家，同时也向用户社区更新蓝筹股公司、大宗商品及更广泛的投资动态 [3] - 团队提供的新闻和独特见解涵盖生物技术、制药、采矿与自然资源、电池金属、石油和天然气、加密货币以及新兴数字和电动汽车技术等多个市场领域 [3] 技术与内容制作 - 公司始终是前瞻性的技术积极采用者 [4] - 人类内容创作者拥有数十年宝贵的专业知识和经验，并利用技术来协助和增强工作流程 [4] - 公司会偶尔使用自动化和软件工具（包括生成式AI），但所有发布的内容均由人类编辑和撰写，遵循内容制作和搜索引擎优化的最佳实践 [5]

Press release – No. 17 / 2025 REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025 Copenhagen, Denmark, December 1, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, is hosting a Capital Markets Day in London on December 11, 2025, featuring presentations from management and external experts in obesity and metabolism. Time: December 11, 2025, from 1.00-5.30pm GMT (2.00-6.30pm CET) ...

公司股价表现 - 礼来公司股价下跌0.8%至1066.96美元，连续第三个交易日下跌，较上周创下的历史高点1112美元有所回落 [1][2] - 尽管近期回调，公司股价仍保持长期上涨趋势，同比涨幅达34% [2] 核心产品定价调整 - 公司下调热门减肥药Zepbound的价格，2.5毫克和5毫克单剂量小瓶的新价格分别为299美元和399美元，原价分别为349美元和499美元 [1] - 新定价将通过公司直接面向消费者的平台LillyDirect提供 [1] 期权市场情绪 - 看涨期权交易活跃，50日看涨/看跌期权成交量比率为2.23，高于过去一年中93%的读数 [2] - 短期交易者近期倾向于看涨押注，Schaeffer's未平仓权益比率为0.70，处于年度第27百分位 [3] - 期权定价显示市场预期波动性较低，Schaeffer's波动率指数为31%，仅高于过去一年中16%的读数 [3]